---
document_datetime: 2025-12-17 23:10:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cejemly.html
document_name: cejemly.html
version: success
processing_time: 0.1113499
conversion_datetime: 2025-12-24 21:24:59.644958
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cejemly

[RSS](/en/individual-human-medicine.xml/243386)

##### Authorised

This medicine is authorised for use in the European Union

sugemalimab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cejemly](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Cejemly is a cancer medicine used in adults to treat a lung cancer called non-small cell lung cancer (NSCLC). It is used:

- in patients whose cancer has spread to other parts of the body (metastatic) and when genetic mutations in the genes for EGFR, ALK, ROS1 or RET are not present. It is used together with platinum-based chemotherapy (other cancer medicines);
- in patients whose cancer has spread within the lung (stage III) and cannot be removed by surgery (unresectable), and whose disease has not worsened after treatment with platinum-based chemotherapy plus radiation therapy. Cejemly is used when the cancer produces a certain amount of a protein called PD-L1 and when genetic mutations in the genes for EGFR, ALK or ROS1 are not present.

Cejemly contains the active substance sugemalimab.

Expand section

Collapse section

## How is Cejemly used?

Treatment with Cejemly should be started and supervised by a doctor experienced in the use of cancer medicines. The medicine can only be obtained with a prescription.

Cejemly is given as an infusion (drip) into a vein over 60 minutes every 3 weeks.

Treatment with Cejemly should continue until it stops working. The doctor may interrupt treatment if certain side effects occur or stop it altogether for certain severe side effects.

For more information about using Cejemly, see the package leaflet or contact your doctor or pharmacist.

## How does Cejemly work?

The active substance in Cejemly, sugemalimab, is a monoclonal antibody (a type of protein) designed to attach to a protein called PD-L1 found on some cancer cells. Cancer cells use this PD-L1protein to bind to certain receptors on the surface of T cells (cells of the immune system). This blocks the activity of T cells and prevents them from attacking the cancer. By attaching to the PD-L1 protein on the cancer cells, sugemalimab stops them from blocking the T cell activity. This increases the ability of the immune system to kill the cancer cells.

## What benefits of Cejemly have been shown in studies?

Two main studies found that Cejemly increased the time people with non-small cell lung cancer lived without their disease getting worse.

**Metastatic NSCLC**

A main study involved 479 adults with metastatic NSCLC with no changes affecting the *EGFR* , *ALK* , *ROS1* or *RET* genes. They received either Cejemly or placebo (a dummy treatment), each given together with platinum-based chemotherapy. The study found that people who received Cejemly lived for an average of 9 months before their cancer got worse compared with 5 months for people who received placebo. Overall, people who received Cejemly with chemotherapy lived for around 25 months, while those who received placebo with chemotherapy lived for around 17 months.

**Locally advanced unresectable NSCLC**

Another main study involved 381 adults with NSCLC that has spread within the lung and cannot be removed by surgery and whose disease has not worsened after treatment with platinum-based chemotherapy plus radiation therapy. People included in the study received either Cejemly or placebo and the study found that people who received Cejemly lived for an average of 10.6 months before their cancer got worse compared with 6.2 months for people who received placebo. Results showed no significant difference in survival between those who had the treatment and those who did not.

## What are the risks associated with Cejemly?

For the full list of side effects and restrictions with Cejemly, see the package leaflet.

The most common side effects with Cejemly (which may affect more than 1 in 10 people) include anaemia (low levels of red blood cells), increased levels of liver enzymes, rash, hyperlipidaemia (high blood fat levels), hyperglycaemia (high blood glucose levels), hyponatraemia (low blood levels of sodium), hypokalaemia (low blood levels of potassium), hypothyroidism (an underactive thyroid gland), hyperthyroidism (an overactive thyroid gland), proteinuria (protein in urine), abdominal (belly) pain, tiredness, arthralgia (joint pain), hypoaesthesia (reduced sensation to touch, pain and temperature) and hypocalcaemia (low blood levels of calcium).

Cejemly is also commonly associated with side effects related to the activity of the immune system on body organs. Most will resolve with appropriate treatment or after interrupting or stopping Cejemly.

## Why is Cejemly authorised in the EU?

Cejemly was shown to increase the time people with metastatic or advanced, unresectable non-small cell lung cancer live without their disease getting worse. For the use in metastatic disease Cejemly also increased the time they lived overall. The use of Cejemly in patients with locally advanced NSCLC after platinum-based chemotherapy and radiotherapy is restricted to those whose cancer produces PD-L1, since a clear benefit was only shown in this group of patients. The safety profile of Cejemly was manageable and no new safety concerns were identified. The European Medicines Agency therefore decided that Cejemly's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Cejemly?

The company that markets Cejemly will provide a patient card about side effects affecting the immune system and when to seek help if these occur. This card will also inform healthcare professionals that the patient is being treated with Cejemly.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cejemly have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Cejemly are continuously monitored. Suspected side effects reported with Cejemly are carefully evaluated and any necessary action taken to protect patients.

## Other information about Cejemly

Cejemly received a marketing authorisation valid throughout the EU on 24 July 2024.

Cejemly : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-35850

English (EN) (151.62 KB - PDF)

**First published:** 05/11/2024

**Last updated:** 10/12/2025

[View](/en/documents/overview/cejemly-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-329)

български (BG) (179.48 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/bg/documents/overview/cejemly-epar-medicine-overview_bg.pdf)

español (ES) (150.31 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/es/documents/overview/cejemly-epar-medicine-overview_es.pdf)

čeština (CS) (176.15 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/cs/documents/overview/cejemly-epar-medicine-overview_cs.pdf)

dansk (DA) (150.96 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/da/documents/overview/cejemly-epar-medicine-overview_da.pdf)

Deutsch (DE) (154.28 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/de/documents/overview/cejemly-epar-medicine-overview_de.pdf)

eesti keel (ET) (147.74 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/et/documents/overview/cejemly-epar-medicine-overview_et.pdf)

ελληνικά (EL) (186.71 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/el/documents/overview/cejemly-epar-medicine-overview_el.pdf)

français (FR) (152.31 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/fr/documents/overview/cejemly-epar-medicine-overview_fr.pdf)

hrvatski (HR) (163.7 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/hr/documents/overview/cejemly-epar-medicine-overview_hr.pdf)

italiano (IT) (149.94 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/it/documents/overview/cejemly-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (181.41 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/lv/documents/overview/cejemly-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (173.45 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/lt/documents/overview/cejemly-epar-medicine-overview_lt.pdf)

magyar (HU) (174.96 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/hu/documents/overview/cejemly-epar-medicine-overview_hu.pdf)

Malti (MT) (178.52 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/mt/documents/overview/cejemly-epar-medicine-overview_mt.pdf)

Nederlands (NL) (153.26 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/nl/documents/overview/cejemly-epar-medicine-overview_nl.pdf)

polski (PL) (178.19 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/pl/documents/overview/cejemly-epar-medicine-overview_pl.pdf)

português (PT) (150.89 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/pt/documents/overview/cejemly-epar-medicine-overview_pt.pdf)

română (RO) (171.55 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/ro/documents/overview/cejemly-epar-medicine-overview_ro.pdf)

slovenčina (SK) (175 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/sk/documents/overview/cejemly-epar-medicine-overview_sk.pdf)

slovenščina (SL) (174.22 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/sl/documents/overview/cejemly-epar-medicine-overview_sl.pdf)

Suomi (FI) (148.21 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/fi/documents/overview/cejemly-epar-medicine-overview_fi.pdf)

svenska (SV) (149.73 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

10/12/2025

[View](/sv/documents/overview/cejemly-epar-medicine-overview_sv.pdf)

Cejemly : EPAR - Risk management plan

English (EN) (1.46 MB - PDF)

**First published:** 05/11/2024

**Last updated:** 27/11/2025

[View](/en/documents/rmp/cejemly-epar-risk-management-plan_en.pdf)

## Product information

Cejemly : EPAR - Product information

English (EN) (1.12 MB - PDF)

**First published:** 05/11/2024

**Last updated:** 27/11/2025

[View](/en/documents/product-information/cejemly-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-343)

български (BG) (973.47 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/bg/documents/product-information/cejemly-epar-product-information_bg.pdf)

español (ES) (1.24 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/es/documents/product-information/cejemly-epar-product-information_es.pdf)

čeština (CS) (1.09 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/cs/documents/product-information/cejemly-epar-product-information_cs.pdf)

dansk (DA) (1009.31 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/da/documents/product-information/cejemly-epar-product-information_da.pdf)

Deutsch (DE) (843.04 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/de/documents/product-information/cejemly-epar-product-information_de.pdf)

eesti keel (ET) (789.23 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/et/documents/product-information/cejemly-epar-product-information_et.pdf)

ελληνικά (EL) (819.87 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/el/documents/product-information/cejemly-epar-product-information_el.pdf)

français (FR) (935.58 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/fr/documents/product-information/cejemly-epar-product-information_fr.pdf)

hrvatski (HR) (976.17 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/hr/documents/product-information/cejemly-epar-product-information_hr.pdf)

íslenska (IS) (1.17 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/is/documents/product-information/cejemly-epar-product-information_is.pdf)

italiano (IT) (1004.45 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/it/documents/product-information/cejemly-epar-product-information_it.pdf)

latviešu valoda (LV) (1.09 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/lv/documents/product-information/cejemly-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.14 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/lt/documents/product-information/cejemly-epar-product-information_lt.pdf)

magyar (HU) (963.99 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/hu/documents/product-information/cejemly-epar-product-information_hu.pdf)

Malti (MT) (1.13 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/mt/documents/product-information/cejemly-epar-product-information_mt.pdf)

Nederlands (NL) (960.82 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/nl/documents/product-information/cejemly-epar-product-information_nl.pdf)

norsk (NO) (885.11 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/no/documents/product-information/cejemly-epar-product-information_no.pdf)

polski (PL) (1.12 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/pl/documents/product-information/cejemly-epar-product-information_pl.pdf)

português (PT) (851.79 KB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/pt/documents/product-information/cejemly-epar-product-information_pt.pdf)

română (RO) (1.05 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/ro/documents/product-information/cejemly-epar-product-information_ro.pdf)

slovenčina (SK) (1.01 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/sk/documents/product-information/cejemly-epar-product-information_sk.pdf)

slovenščina (SL) (1.03 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/sl/documents/product-information/cejemly-epar-product-information_sl.pdf)

Suomi (FI) (1.02 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/fi/documents/product-information/cejemly-epar-product-information_fi.pdf)

svenska (SV) (1.49 MB - PDF)

**First published:**

05/11/2024

**Last updated:**

27/11/2025

[View](/sv/documents/product-information/cejemly-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000261157 21/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cejemly : EPAR - All authorised presentations

English (EN) (42.54 KB - PDF)

**First published:** 05/11/2024

[View](/en/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-918)

български (BG) (45.42 KB - PDF)

**First published:**

05/11/2024

[View](/bg/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.34 KB - PDF)

**First published:**

05/11/2024

[View](/es/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_es.pdf)

čeština (CS) (44.47 KB - PDF)

**First published:**

05/11/2024

[View](/cs/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.96 KB - PDF)

**First published:**

05/11/2024

[View](/da/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.58 KB - PDF)

**First published:**

05/11/2024

[View](/de/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.75 KB - PDF)

**First published:**

05/11/2024

[View](/et/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.63 KB - PDF)

**First published:**

05/11/2024

[View](/el/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_el.pdf)

français (FR) (43.57 KB - PDF)

**First published:**

05/11/2024

[View](/fr/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (44.04 KB - PDF)

**First published:**

05/11/2024

[View](/hr/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.74 KB - PDF)

**First published:**

05/11/2024

[View](/is/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_is.pdf)

italiano (IT) (43.27 KB - PDF)

**First published:**

05/11/2024

[View](/it/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (44.46 KB - PDF)

**First published:**

05/11/2024

[View](/lv/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (44.38 KB - PDF)

**First published:**

05/11/2024

[View](/lt/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (44.3 KB - PDF)

**First published:**

05/11/2024

[View](/hu/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (43.84 KB - PDF)

**First published:**

05/11/2024

[View](/mt/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (43.6 KB - PDF)

**First published:**

05/11/2024

[View](/nl/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.84 KB - PDF)

**First published:**

05/11/2024

[View](/no/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_no.pdf)

polski (PL) (45.22 KB - PDF)

**First published:**

05/11/2024

[View](/pl/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.85 KB - PDF)

**First published:**

05/11/2024

[View](/pt/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_pt.pdf)

română (RO) (44.01 KB - PDF)

**First published:**

05/11/2024

[View](/ro/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (44.27 KB - PDF)

**First published:**

05/11/2024

[View](/sk/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.1 KB - PDF)

**First published:**

05/11/2024

[View](/sl/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.14 KB - PDF)

**First published:**

05/11/2024

[View](/fi/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (43.52 KB - PDF)

**First published:**

05/11/2024

[View](/sv/documents/all-authorised-presentations/cejemly-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cejemly Active substance sugemalimab International non-proprietary name (INN) or common name sugemalimab Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01FF11

### Pharmacotherapeutic group

- Antineoplastic agents
- monoclonal antibodies and antibody drug conjugates
- PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors

### Therapeutic indication

Cejemly in combination with platinum-based chemotherapy is indicated for the first line treatment of adults with metastatic non small cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Cejemly as monotherapy is indicated for the treatment of unresectable stage III NSCLC with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy.

## Authorisation details

EMA product number EMEA/H/C/006088

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Cstone Pharmaceuticals Ireland Limited

117-126 Sheriff Street Upper Dublin 1 D01 YC43 Ireland

Opinion adopted 30/05/2024 Marketing authorisation issued 24/07/2024 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cejemly : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (180.68 KB - PDF)

**First published:** 17/03/2025

**Last updated:** 27/11/2025

[View](/en/documents/procedural-steps-after/cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cejemly : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (103.77 KB - PDF)

**First published:** 13/12/2024

**Last updated:** 17/03/2025

[View](/en/documents/procedural-steps-after/cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Cejemly-VR-0000261157 : EPAR - Assessment report

Reference Number: EMADOC-1700519818-2465582

English (EN) (4.18 MB - PDF)

**First published:** 27/11/2025

[View](/en/documents/variation-report/cejemly-vr-0000261157-epar-assessment-report_en.pdf)

Cejemly-PSUSA-00011080-202412 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMADOC-1700519818-2563148

English (EN) (165.29 KB - PDF)

**First published:** 27/10/2025

[View](/en/documents/scientific-conclusion/cejemly-psusa-00011080-202412-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Cejemly (EMAVR0000261157)

Adopted

Reference Number: EMADOC-1700519818-2464690

English (EN) (120.08 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cejemly-emavr0000261157_en.pdf)

## Initial marketing authorisation documents

Cejemly : EPAR - Public assessment report

Reference Number: EMA/380155/2024

English (EN) (3.95 MB - PDF)

**First published:** 05/11/2024

[View](/en/documents/assessment-report/cejemly-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cejemly

Reference Number: EMA/CHMP/224098/2024

English (EN) (110.99 KB - PDF)

**First published:** 31/05/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cejemly_en.pdf)

#### News on Cejemly

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 October 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-october-2025) 17/10/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024) 31/05/2024

**This page was last updated on** 10/12/2025

## Share this page

[Back to top](#main-content)